Dr. G. Bozet, MD

NAFLD is an increasingly prevalent and potentially severe liver disease, emphasising the need for implementation of widely supported care paths for patients at risk for advanced stages of NAFLD. In this review article by A. M. van Dijk et al. (Amsterdam University Medical Centre, The Netherlands), after...

These Korean guidelines, organised in accordance with proposals by the approval of the Korean Association for the Study of the Liver (KASL) Board of Executives, provide clinical information and direction to healthcare providers involved in the diagnosis and treatment of NAFLD patients. ...

The majority of NAFLD patients die of cardiovascular disease. For this reason, management of this condition requires a multidisciplinary team. However, important misconceptions remain among primary care providers. NAFLD should be understood as part of a systemic disease characterized ...

Several studies provide evidence for an association between MAFLD and atherosclerosis and cardio-metabolic disorders, including cardiovascular diseases such as coronary heart disease and stroke. Therefore, the combination of MAFLD/NASH is associated with vascular risk and CVD progression, but the underlying mechanisms...

Exercise could mediate its beneficial effects directly on the liver and indirectly via extrahepatic pathways, forming a dose-response relationship with NAFLD in terms of prevalence and disease severity...

General strategies have been proposed to manage NAFLD. They include: (a) lifestyle change in order to promote weight loss by diet and physical activity, (b) control of the main cardiometabolic risk factors, (c) correction of all modifiable risk factors leading the development and progression of advanced forms of NAFLD, (d) and prevention...

In this review, L. J. M. Heyens et al. (Hasselt University, Belgium, Maastricht University, Netherlands, and, Ziekenhuis Oost-Limburg, Belgium) give an overview of the pathogenic mechanisms of the evolution from isolated steatosis to fibrosis. The authors also discuss of the current and future diagnostic biomarkers and anti-fibrotic drugs...

While the successful treatment of hepatitis B and C reduced the burden of liver disease related to viral hepatitis, NAFLD) or NASH) are nowadays the leading causes of hepatic fibrosis worldwide. In this review, F. Tacke et al. (Charité University Medicine, Berlin, Germany) discuss recent advances in antifibrotic prevention and therapy...

In their systematic review and meta-analysis, V. Houttu et al. (Amsterdam University Medical Center, The Netherlands) summarise and assess the evidence for dietary interventions NAFLD patients. In these patients, Mediterranean and hypocaloric dietary interventions favouring unsaturated fatty acids ...

In an ongoing, community-based, cohort-study in Sri Lanka, participants were randomly selected in 2007, and were reassessed in 2014 to evaluate new-onset metabolic traits and cardiovascular-events. M. A. Niriella et al. (University of Kelaniya, Sri Lanka) compared baseline characteristics, metabolic traits and cardiovascular-events after...

Elena Kotsiliti, associate editor at Nature Reviews Gastroenterology & Hepatology, presents the results of the phase IIb NATIVE double-blind, randomized, placebo-controlled trial. This trial investigated lanifibranor (a pan-proliferator–activated receptor agonist) in patients with severe nonalcoholic steatohepatitis (NASH) without cirrhosis...

The presence or recurrence of metabolic syndrome following liver transplantation can contribute to the development and recurrence of NAFLD in the liver allograft...